Daniel Getts
Chief Executive Officer & Co-Founder CREATE Medicines
Seminars
Tuesday 21st July 2026
In Vivo Immune Cell Programming with mRNA-LNP Therapeutics
8:30 am
- In vivo CAR mRNA-LNP platform selectively generates CAR-T, CAR-NK, and myeloid CAR cells directly in patients
- Clinically validated with data from 50+ patients and demonstrated tolerable repeat dosing
- Best-in-class in vivo CARs across oncology and autoimmunity, including first clinical responses with in vivo CARs outside blood cancers
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
